Hubro Therapeutics Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
Liquidation
Hubro Therapeutics General Information
Description
Developer of novel cancer vaccines designed to prolong and transform the quality of the lives of cancer patients. The company's medicines are for the activation of anti-cancer T-cell immune responses and target neo-antigens caused by genetic frameshift mutation associated with MSI and cancer, enabling patients to address their unmet medical conditions.
Contact Information
Website
www.hubrotherapeutics.comCorporate Office
- Ullernchaussée 64
- 0379 Oslo
- Norway
Corporate Office
- Ullernchaussée 64
- 0379 Oslo
- Norway
Hubro Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Bankruptcy: Liquidation | 07-Mar-2024 | Completed | Bankruptcy: Liquidation | |||
| 5. Later Stage VC | 07-Feb-2023 | Completed | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC | 01-Jul-2021 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC | 30-May-2020 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC | 30-Jun-2019 | $829K | $829K | Completed | Pre-Clinical Trials | |
| 1. Grant | 14-Jan-2019 | $80.9K | Completed | Startup |
Hubro Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Hubro Therapeutics Patents
Hubro Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024149791-A1 | A primer | Inactive | 11-Jan-2023 | ||
| WO-2024052542-A2 | A peptide cocktail | Inactive | 09-Sep-2022 | ||
| WO-2024052542-A3 | A peptide cocktail | Inactive | 09-Sep-2022 | ||
| GB-202205105-D0 | A primer | Inactive | 07-Apr-2022 | ||
| AU-2022308403-A1 | A primer | Inactive | 09-Jul-2021 | C12Q1/6827 |
Hubro Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Hubro Therapeutics Investments (1)
Hubro Therapeutics’s most recent deal was a Corporate Asset Purchase with Circio (Gm-Csf Vaccine Adjuvant in Lysaker, Norway) for . The deal was made on 01-Nov-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Circio (Gm-Csf Vaccine Adjuvant in Lysaker, Norway) | 01-Nov-2022 | Corporate Asset Purchase | Buildings and Property |
Hubro Therapeutics FAQs
-
When was Hubro Therapeutics founded?
Hubro Therapeutics was founded in 2018.
-
Where is Hubro Therapeutics headquartered?
Hubro Therapeutics is headquartered in Oslo, Norway.
-
What is the size of Hubro Therapeutics?
Hubro Therapeutics has 12 total employees.
-
What industry is Hubro Therapeutics in?
Hubro Therapeutics’s primary industry is Drug Discovery.
-
Is Hubro Therapeutics a private or public company?
Hubro Therapeutics is a Private company.
-
What is Hubro Therapeutics’s current revenue?
The current revenue for Hubro Therapeutics is .
-
How much funding has Hubro Therapeutics raised over time?
Hubro Therapeutics has raised $9.7M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
